Canada Markets closed

Radius Health, Inc. (RDUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.77-0.26 (-3.70%)
At close: 04:00PM EST
6.75 -0.02 (-0.30%)
After hours: 06:04PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close7.03
Bid6.38 x 1000
Ask6.78 x 4000
Day's Range6.76 - 7.27
52 Week Range5.92 - 26.16
Avg. Volume1,274,000
Market Cap320.507M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateFeb. 23, 2022 - Feb. 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.25
  • GlobeNewswire

    Radius Health Completes Business Adjustment

    Completion of three pivotal trials in 2021 enables restructuring of the operating infrastructureNon-Sales headcount reduced by approximately 20%Reductions focused on areas that supported abaloparatide clinical and regulatory activitiesCompany to provide Q4 & FY 2021 results and 2022 outlook during earnings on February 24 BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), has completed an adjustment of its business. The catalyst for the chang

  • Zacks

    Are Options Traders Betting on a Big Move in Radius Health (RDUS) Stock?

    Investors need to pay close attention to Radius Health (RDUS) stock based on the movements in the options market lately.

  • GlobeNewswire

    Radius Announces Update on TYMLOS® (abaloparatide) Label

    FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021The boxed warning had referred to the potential risk of osteosarcomaAction follows review of long-term post-marketing data for TYMLOS and PTH class of drugs BOSTON, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label, including the removal of the boxed